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Supplemental Methods 
Patients and treatment 
Eligible patients had a diagnosis of non-germinal center B-cell (GCB) diffuse large B-cell lymphoma (DLBCL), 
follicular lymphoma (FL), mantle cell lymphoma (MCL), or other indolent non-Hodgkin lymphoma (NHL) 
(marginal zone lymphoma [MZL], small lymphocytic lymphoma [SLL], or lymphoplasmacytic lymphoma [LPL]) 
as documented by medical records and with histology based on the World Health Organization criteria that 
were current at the time of patient enrollment.1-3 DLBCL subtyping was performed locally according to the Hans 
classification algorithm.4 FL was limited to histological grades 1, 2, and 3a. MZL could be splenic, nodal, or 
extranodal. Patients with SLL had an absolute lymphocyte count of <5 x 109/L at initial diagnosis, and those 
with LPL had measurable disease defined as serum monoclonal immunoglobulin M > 0.5 g/dL or meeting at 
least 1 of the recommendations from the Second International Workshop on Waldenström’s Macroglobulinemia 
for requiring treatment. No central independent histopathological review was performed. 
The disease and dose chosen for expansion cohorts were based on emerging safety, efficacy, 
pharmacokinetic (PK), and pharmacodynamic results of the dose-escalation phase. Based on the safety, PK 
and biomarker data from a previous study5, the initial dose regimens were tirabrutinib (TIRA) 20 mg QD + 
idelalisib (IDELA) 50 mg BID, and TIRA 40 mg QD + entospletinib (ENTO) 200 mg QD. 
Endpoint definitions and analysis methods 
Analysis results are presented using descriptive statistics. For categorical variables, the number and 
percentage of subjects in each category are presented; for continuous variables, this may include the number 
of subjects (n), median, first quartile (Q1), third quartile (Q3), minimum, and maximum. Overall response rate 
(ORR) was defined as the proportion of patients who achieve a complete response (CR) or partial response 
(PR) based on standardized response criteria for malignant lymphomas.6-8 Best overall response (BOR) was 
defined as the best response recorded during the follow-up period after first dose prior to the time of initiation 
of anticancer therapy other than the study treatment. ORR is defined as the proportion of subjects who achieve 
a BOR of CR or PR during the study, except for patients with LPL for whom ORR includes CR, PR, very good 
PR, and minor PR. Progression-free survival (PFS) was analyzed by Kaplan-Meier methods, and was defined 
as the interval from the start of the study therapy to the earlier of the first documentation of definite 
radiographic disease progression or death from any cause. 
Pharmacokinetic assessments 
PK assessments were conducted as previously described.9 Patients in the dose-escalation cohorts underwent 
intensive PK sampling on day 1, day 2, and day 8 of the first treatment cycle, and sparse PK sampling up to 
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Cycle 6 of treatment. TIRA and IDELA plasma concentrations were determined using validated bioanalytical 
assays. PK parameters were estimated by standard noncompartmental methods using Phoenix WinNonlin® 
7.0 software (Certara, Princeton, NJ, US). PK concentrations and parameters were summarized using 
descriptive statistics.  
Exploratory biomarker analyses 
When available, archival tumor tissue was collected from DLBCL patients. Minimal residual disease (MRD) 
analysis for DLBCL patients was performed during cycle 1 and at disease progression/end of treatment by 
Adaptive Biotechnologies (Seattle, WA, US). Briefly, pretreatment FFPE tissue was analyzed to identify tumor-
specific clonotypes on the basis of the ClonoSeq method.10 Circulating tumor DNA (ctDNA) from serial plasma 
samples was then used for MRD surveillance on treatment. MRD positivity was defined as the level of tracked 
clonotypes exceeding detection limit, which is sample-specific and determined based on the BCR repertoire 




The pharmacokinetics of TIRA in patients with NHL were consistent with previous studies.17, 25 Mean (% CV) 
TIRA peak plasma concentrations at 1.5-4 hours post-dose were 268 (27) and 381 (41) ng/mL in DLBCL 
patients receiving 80 mg (n=4) and 160 mg (n=3) TIRA QD (in combination with 100 mg IDELA QD). At the 80 
mg TIRA + 100 mg IDELA QD dose level, peak TIRA plasma concentrations in other NHL (n=8) patients were 
268 (34) ng/mL.  
Coadministration of TIRA with IDELA did not affect TIRA PK; however, TIRA increased IDELA exposures at a 
higher dose (160 mg QD TIRA) that was evaluated in DLBCL patients.25 IDELA exposures (AUCtau, mean [% 
CV]) were 9490 (34.4) and 19,300 (29.1) h*ng/mL in DLBCL patients assigned to 100 mg QD IDELA, in 
combination with 80 mg QD TIRA and 160 mg TIRA, respectively. The daily IDELA exposures (mean [%CV]) 
observed in this study were within the range of those previously established to be safe in patients with CLL and 
FL (150 mg BID IDELA; Cmax = 1861 [43%], AUCtau = 10598 [41%].2 
ENTO PK was comparable at the 80 mg TIRA QD and 160 mg TIRA QD doses. In 3 patients receiving 80 mg 
TIRA QD + 400 mg ENTO QD, mean (% CV) peak ENTO plasma concentration on cycle 1 day 8 was 1249 
(42%) ng/mL, compared with 827 (37%) ng/mL in 4 patients receiving 160 mg TIRA QD + 400 mg ENTO. 
Biomarkers 
Exploratory biomarker analyses were performed for the DLBCL cohort. After identifying patient-specific B-cell 
clones from archival tumor tissue, clone tracking from ctDNA was successful in 8 patients in the TIRA/IDELA 
group and in 22 patients on TIRA/ENTO (Supplemental Figure 5). In the TIRA/IDELA group, all patients with 
PD and SD had MRD detectable at all time points. Two patients with PR temporarily had no detectable MRD 
but did not maintain this status, while 1 patient with PR had no detectable ctDNA at baseline and remained 
MRD negative for 15 cycles (and is still on treatment). In the TIRA/ENTO group, 1 patient had no detectable 
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ctDNA at baseline, but became MRD positive at end of treatment. The only patient with a CR who had ctDNA 
tracking turned MRD negative on treatment at the first measured time point and remained MRD negative until 
end of treatment. 
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Supplemental Table 1. Dose-escalation cohorts (3+3 design).  
 
 Group A Group Ba 
Dose Level TIRA IDELA TIRA IDELA 
1b 20 mg QD 50 mg BID ▬ ▬ 
2 40 mg QD 50 mg BID 20 mg BID 50 mg BID 
3 80 mg QD 50 mg BID ▬ ▬ 
4 80 mg QD 100 mg QD ▬ ▬ 
5c 160 mg QD 100 mg QD ▬ ▬ 
Dose Level TIRA ENTO TIRA ENTO 
1 40 mg QD 200 mg QD ▬ ▬ 
2a 80 mg QD 200 mg QD 40 mg QD 400 mg QD 
3 150 mg QD 200 mg QD 80 mg QD 400 mg QD 
4c ▬ ▬ 160 mg QD 400 mg QD 
 
aTIRA/IDELA group B was closed to further enrollment following dose-limiting toxicity of neutropenia. 
bInitially, 3 patients were enrolled in dose level 1A. The first cycle consisted of 28 days (1 day single agent TIRA and 27 days of 
combination treatment), and each subsequent cycle consisted of 28 days of combination treatment. If only 1 dose-limiting toxicity (DLT) 
occurred within 28 days from cycle 1, day 1, dose level 1A was expanded to enroll 3 additional patients. Subsequently if ≥2 patients 
experienced DLT, development of the combination of TIRA and IDELA was to be discontinued. If no DLT occurred in 3 patients or <2 
DLTs occurred in up to 6 patients in Cohort 1A, then Cohort 2A was initiated. For the remainder of dose escalation, higher cohorts 
began enrollment if no DLTs in 3 patients or <2 DLTs in up to 6 patients were observed. If a second DLT was observed in any cohort, 
the maximum tolerated dose (MTD) of TIRA combined with IDELA or ENTO was considered to have been exceeded, and the prior dose 
level was considered to be the MTD. The MTD for TIRA once-daily was assessed separately from the MTD for TIRA twice daily. Once 
all 3 treatment cohorts were open, the choice of enrolling a patient into a cohort and dosing level was based on the treatment slots open 
at the time of screening and at the discretion of the investigator. 
cThis dose level was only administered to DLBCL patients.
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Supplemental Table 2. Definition of dose-limiting toxicitiesa  
 
Grade ≥4 • All grade ≥4 hematological toxicities persisting for >7 days. • All grade ≥4 nonhematologic laboratory abnormalities. 
Grade ≥3 
All grade ≥3 nonhematological toxicities except for tumor lysis or alopecia, or 
grade 3 nausea, vomiting, diarrhea, or constipation that resolves within 72 hours 
with medical intervention. 
Grade ≥2 
Grade ≥2 nonhematologic TEAE that in the opinion of the investigator is of 
potential clinical significance such that further dose escalation would expose 
subjects to unacceptable risk. 
Febrile Neutropenia 
Febrile neutropenia defined as ANC <1.0 x 109/L with a single temperature 
>38.3°C (101°F) or sustained temperature ≥38°C (100.4°F) for more than 1 hour. 
 
aFor toxicities occurring between day 1 and day 28 of a dosing cycle. 
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Duration of exposure to TIRA, 















Dose interruption, n (%) 
patients 7 (41) 7 (70) 1 (100) 11 (92) 10 (25.6) 9 (34.6) 4 (36) 7 (47) 
Adverse event 7 (41) 7 (70) 1 (100) 8 (67) 6 (15.4) 6 (23.1) 4 (36) 5 (33) 
Noncompliance 0 0 0 2 (17) 2 (5.1) 0 0 0 
Other 0 0 0 1 (8) 2 (5.1) 3 (11.5) 0 2 (13) 
Dose modification, n (%) 
patients 3 (18) 1 (10) 1 (100) 4 (33) 2 (5.1) 1 (3.8) 3 (27) 2 (13) 
Adverse event 0 0 1 (100) 0 0 0 0 0 
Per protocol 3 (18) 1 (10) 0 1 (8) 2 (5.1) 1 (3.8) 2 (18) 1 (7) 
Noncompliance 0 0 0 1 (8) 0 0 0 0 
Other 0 0 0 2 (17) 0 0 1 (9) 1 (7) 
Duration of exposure to IDELA/ 















Dose interruption, n (%) 
patients 7 (41) 6 (60) 0 9 (75) 10 (25.6) 8 (30.8) 3 (27) 6 (40) 
Adverse event 7 (41) 6 (60) 0 7 (58) 6 (15.4) 5 (19.2) 3 (27) 4 (27) 
Noncompliance 0 0 0 1 (8) 2 (5.1) 0 0 0 
Other 0 0 0 1 (8) 2 (5.1) 3 (11.5) 0 2 (13) 
Dose modification, n (%) 
patients 2 (12) 0 0 3 (25) 3 (7.7) 1 (3.8) 2 (18) 1 (7) 
Adverse event 0 0 0 0 1 (2.6) 0 0 0 
Per protocol 2 (12) 0 0 1 (8) 2 (5.1) 1 (3.8) 2 (18) 1 (7) 
Noncompliance 0 0 0 1 (8) 0 0 0 0 
Other 0 0 0 1 (8) 0 0 0 0 
 
*LPL, MZL, SLL.
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Supplemental Table 4. Laboratory abnormalities of interest.* 
 





Any grade Grade ≥3 Any grade Grade ≥3 
Any laboratory abnormality 39 (100)* 27 (69) 88 (98) 51 (57) 
Chemistry 
Albumin decreased 
Alkaline phosphatase increased 
Alanine transaminase increased 
Amylase increased 
Aspartate transaminase increased 
Creatinine clearance decreased 
Creatinine increased 
g-glutamyl transferase increased 
Hyperbilirubinemia 




















































































































Activated partial thromboplastin time 



















White blood cell count decreased 












































*Percentages are calculated based on number of patients with post-baseline values. 
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TIRA/IDELA, N 17 10 1 12 










Time to response,  









Duration of response, KM-estimated 









Best overall response, n (%) 
Complete response 
Very good partial response (LPL) 
Partial response 









































TIRA/ENTO, N 39 26 11 15 










Time to response, 









Duration of response, KM-estimated 









Best overall response, n (%) 
Complete response 
Very good partial response (LPL) 
Partial response 










































*Overall response rate = complete response + partial response for all subtypes except Waldenström’s macroglobulinemia, where overall 
response rate also includes very good partial response and minor response. 
†Discontinued study or started new anticancer therapy before first assessment. 
‡LPL, MZL, SLL. 
KM, Kaplan-Meier; NR, not reached. 
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Supplemental Table 6. Kaplan-Meier estimated duration of response. 
 
 TIRA/IDELA N=40 
TIRA/ENTO 
N=91 
Diffuse large B-cell lymphoma 6.4 (3.9, NR) NR 
Follicular lymphoma 8.4 (3.0, 13.8) 16.6 (11.5, 17.3) 
Mantle cell lymphoma 10.7* 15.3 (14.0, 16.6) 
Marginal zone lymphoma 2.9 (2.5, 3.3) NR 
Small lymphocytic lymphoma 19.3* NR 
Waldenström’s macroglobulinemia/lymphoplasmacytic 
lymphoma NR NR 
 
Data show median (Q1, Q3) duration of response in months. 
 
*N=1 MCL and N=2 SLL patients in the TIRA/IDELA group. 
NR, not reached. 
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Supplemental Figure 1. Patient disposition. 
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Supplemental Figure 2. Patient exposure and disposition in patients with DLBCL, FL, and Other NHL.  
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Supplemental Figure 3. Best SPD change from baseline in patients with A) non-GCB DLBCL, B) FL, and C) 
Other NHL. 
A. IDELA: Patients with missing values (n=2) are not shown; ENTO: Patients with missing values (n=5) are 
not shown 
B. IDELA: Patients with missing values (n=2) are not shown; ENTO: Patients with missing values (n=3) are 
not shown 
C. IDELA: Patients with missing values (n=4) are not shown; ENTO: Patients with missing values (n=5) are 
not shown 
Other NHL = SLL, MCL, MZL, LPL; SPD, sum of the products of greatest perpendicular diameters. 
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Supplemental Figure 5. MRD assessment by ctDNA clone tracking in DLBCL patients receiving A) TIRA/IDELA 







Cycle 1 sample was obtained before treatment and served as baseline.  
 
CR, complete response; EOT, end of treatment; NE, not evaluable; PD, progressive disease; PR, partial response; SD, stable disease.  
